Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity

Biomedicine and Pharmacotherapy

Volumn 64, Issue 1, 2010, Pages 73-76

  Jenderny, Sara ^a   Lin, He ^a   Garrett, Tracy ^a   Tew, Kenneth D ^a   Townsend, Danyelle M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemoprotection; Cisplatin; Glutathione; Nephrotoxicity; NOV 002

Indexed keywords

CISPLATIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE DISULFIDE; NOV 002; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW SUPPRESSION; CATALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; ENZYME SUBSTRATE; FEMALE; KIDNEY; KIDNEY PROXIMAL TUBULE; KIDNEY STRUCTURE; KIDNEY TUBULE DAMAGE; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; URINARY CAST;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CREATININE; DRUG COMBINATIONS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLUTATHIONE DISULFIDE; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MICE; MICE, INBRED C57BL;

EID: 73149109267     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.09.009     Document Type: Article

References (12)

1. Pazoles C.J., and Gernstein H. NOV-002, a chemoprotectant/immunomodulator, added to first line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): a randomized phase 1/2, open label, controlled study. Am Soc Oncol (2006) [abstract # 17021]
2. Townsend D.M., Pazoles C.J., and Tew K.D. NOV-002, a mimetic of glutathione disulfide. Expert Opin Investig Drugs 17 7 (2008) 1075-1083
3. Townsend D.M., et al. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer Res 68 8 (2008) 2870-2877
4. Townsend D.M., et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14 1 (2003) 1-10
5. Townsend D.M., and Hanigan M.H. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther 300 1 (2002) 142-148
6. Townsend D.M., et al. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of Cisplatin. Drug Metab Dispos 31 6 (2003) 705-713
7. Glantz S.A. Primer of biostatistics. 3rd Edition. (1992), McGraw Hill, New York
8. Plaxe S., et al. Phase I trial of cisplatin in combination with glutathione. Gynecol Oncol 55 1 (1994) 82-86
9. Smyth J.F., et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 8 6 (1997) 569-573
10. Schmidinger M., et al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr 112 14 (2000) 617-623
11. Daley-Yates P.T., and McBrien D.C. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33 19 (1984) 3063-3070
12. Townsend D.M., et al. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother 63 2 (2009) 79-85